East Windsor, NJ—Sabinsa’s Macumax has been shown in a new study to support eye health in patients with early-stage dry-type AMD.
Macumax is a mixture of zeaxanthin, lutein, piperine, bilberry, saffron, and zinc monomethionine.
40 subjects participated in the 90-day, open-label clinical study. They received one capsule of the product twice daily. Patients were assessed for subjective and objective symptoms at baseline and after treatment, and were physically examined. Baseline values were compared with values after treatment on days 30, 60, and 90.
Overall, the study found that patients showed improvement on subjective symptoms, such as vision scores. The changes in diminished and distorted vision scores were found to be significant from day 60. In terms of objective symptoms, only 40% of the subject had abnormal Amsler’s grid aberration scores on day 90, compared with 77.5% of subjects at the beginning of the study. No adverse events were reported.
Noting that the study was limited by a small group of subjects, a short duration, and lack of a control group, the researchers nonetheless concluded that “the findings provide clinical evidence that a 90-day oral supplementation of Macumax was safe and helpful in preventing early-stage dry-type AMD without further progression of the disease.” The researchers called for further clinical study.
“The maintenance of AMD symptoms from further deterioration is of paramount importance,” commented Sabinsa Founder and Chairman Dr. Muhammed Majeed in a press release. “Nutritional supplementation seems to hold great promise in that area. We are happy with the trial outcome, and look forward to continuing investigations.”